Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

er-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys and Copegus are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. The study finds ...
(Date:7/29/2014)... July, 29  2014 ISPE—the International Society for ... John Bournas as President and CEO, succeeding ... leave the Society last fall.  Mr. Bournas takes ... the healthcare association industry as well as significant ... clear vision for the expansion of its global ...
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- MHG Medical Management ... launched its Medical Equipment and X-ray Annual ... are tailored to the cruise industry,s unique requirements.  ... operators to propose that they should develop a ... program is intended to create standardized processes and ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2
... (NYSE: WPI ), a leading specialty global ... and Chief Executive Officer, will provide an overview and ... Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May ... Hotel in New York, New York.  The presentation will ...
...  Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has ... Administration for its abbreviated new drug application (ANDA) for ... have already begun.  (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ... U.S. store brand market is bioequivalent to Novartis, Prevacid® ...
Cached Medicine Technology:Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference 2Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules 2
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Chinese in vitro diagnostic ...
(Date:7/30/2014)... Angeles, California (PRWEB) July 30, 2014 ... an online dating community where motorcycle enthusiasts congregate, ... on the site that were revealed by BikerKiss indicate ... increase in the past 3 years. , Members on ... US, UK, Canada, Australia and some other European countries ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive bodybuilding guide for men who ... by up to 50 pounds in within a few ... that will help keep their shoulders healthy and avoid the ... the Critical Bench Program 2.0 uncovers to learners the reason ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... of Melinda J. Helbock A.P.C. are announcing that they are ... from the negative effects of asbestos exposure. , “Symptoms ... that were exposed to the toxin 30 plus years ago ... Melinda Helbock, Founder of The Law Office of Melinda J. ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Single Women Motorcycle Riders In Rapid Increase 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... the long-term consequences of too much sun exposure can be ... anyone who's spent a day basking on the beach. ,Characterized ... to the touch, sunburn is a sure, almost immediate sign ... been damaged by the sun's ultraviolet rays. And the consequences ...
... havoc on a woman’s bones and a new study reveals ... Researchers know bone loss occurs after menopause, increasing chances of ... and strength. ,The Swedish study involved 146 women who were ... done to determine bone size and density. //All fractures related ...
... week may cut their risk of Alzheimer's by more than ... that diet may affect a person's chances of developing the ... that people 65 and older who had fish once a ... those who never or rarely ate fish. The meals included ...
... you don't use your mind regularly through activities such ... you risk losing some of your cognitive abilities as ... appearing in the June 19 issue of the New ... of Medicine in New York City found seniors who ...
... Clinic in Rochester, Minn., say they have found a ... is an allergic inflammatory reaction of the esophagus. The ... research shows a topical corticosteroid therapy is effective for ... of high levels of eosinophils. Eosinophils are a type ...
... women with colon cancer that has advanced beyond the ... outcome, according to a recent study. In addition to ... may have an increased risk of cancer recurrence, at ... long-term outcomes and treatment-related side effects in colon cancer ...
Cached Medicine News:
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: